Paving the Way for First-Line Oral Doublet in CLL

An all-oral combination of the BTK inhibitor acalabrutinib (Calquence, AstraZeneca) and the BCL-2 inhibitor ...

JANUARY 29, 2025

FDA Approves Calquence With Bendamustine and Rituximab for Previously Untreated Mantle Cell Lymphoma

The FDA has granted traditional approval to acalabrutinib (Calquence, AstraZeneca) with bendamustine and rituximab ...

JANUARY 21, 2025

BTK Inhibitors, Other Blood Cancer Drugs Are Being Tapped for COVID-19

Studies are underway exploring immunomodulating agents approved for hematologic malignancies in the treatment of ...

JULY 23, 2020

More Specific BTK Inhibitor Shows High Relative Rates of Response in CLL

ORLANDO, FLA.—In a phase 3 trial, acalabrutinib, a second-generation Bruton’s tyrosine kinase (BTK), ...

JANUARY 27, 2020

FDA Approves Calquence for CLL and SLL

The FDA granted supplemental approval to acalabrutinib (Calquence, AstraZeneca) for the treatment of adults with ...

NOVEMBER 21, 2019

FDA Approves BTK Inhibitor Calquence for Mantle Cell Lymphoma

The FDA granted accelerated approval to acalabrutinib (Calquence, AstraZeneca) for the treatment of adults with ...

NOVEMBER 1, 2017

Acalabrutinib Granted Breakthrough Therapy Designation for MCL

Acalabrutinib was granted breakthrough therapy designation for treatment of patients with mantle cell lymphoma ...

AUGUST 2, 2017